BioMarin Pharmaceutical Inc (BMRN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

105 DIGITAL DRIVE NOVATO, CA 94949

Biomarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of three approved products and multiple investigational product candidates. Approved products include Aldurazyme, Naglazyme, and Orapred.

Data as of 2020-08-01
Market Cap21.666 Billion Shares Outstanding180.837 Million Avg 30-day Volume1.378 Million
P/E Ratio196.3 Dividend Yield EPS0.62
Price/Sales15.284 Price cash flow ratio250.9 Price free cash flow ratio-786.3
Book Value17.92 Price to Tangible Book8.47 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.21399
BETA1.04687 52-week High/Low131.945 / 62.88 Stddev0.097367
View SEC Filings from BMRN instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 9 8 (0.52%)
13F Filers holding this stock: 478 119 (7.79%)
Aggregate 13F shares on 03/31/2020: 173.529 Million 63.725 Million
Aggregate 13F shares on 12/31/2019: 172.75 Million 59.331 Million
Percent change: 0.45% 7.41%
Funds creating new positions: 74 23
Funds Adding to an existing position: 181 41
Funds closing out their position: 42 15
Funds reducing their position: 158 46
Heat Map Ranking for 03/31/2020 83
Heat Map Ranking for 12/31/2019 83
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BMRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BMRN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

168.8 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

164.4 Thousand total shares from 7 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ASELAGE STEVE

  • Director
63,905 2020-07-24 0

GREY MICHAEL G

  • Director
62,290 2020-07-22 1

FUCHS HENRY J PRESIDENT, WORLDWIDE R&D

  • Officer
102,995 2020-07-20 7

ACOSTA ANDREA GVP, CHIEF ACCOUNING OFFICER

  • Officer
14,674 2020-07-17 2

KAKKIS EMIL D PRESIDENT & CEO

  • Officer
  • Director
3,030,782 2020-07-13 0

PYOTT DAVID E I

  • Director
0 2020-07-01 1

KLEIN JOSEPH III

  • Director
16,783 2020-07-01 0

BIENAIME JEAN JACQUES

  • Director
9,190 2020-06-30 18

HOMBACH ROBERT J.

0 2020-06-30 1

DERE WILLARD H

  • Director
13,290 2020-06-26 2

BATE KENNETH

  • Director
0 2020-06-18 0

ANDERSON ELIZABETH M

  • Director
38,798 2020-06-17 1

LEWIS ALAN

  • Director
0 2020-06-11 0

FALBERG KATHRYN E

  • Director
42,760 2020-06-11 0

COOPER JEFFREY H

  • Director
0 2020-06-09 0

LAWLIS V BRYAN

  • Director
0 2020-06-08 5

YOUNG WILLIAM D

  • Director
0 2020-06-01 0

MEIER RICHARD A

  • Director
84,340 2020-05-27 1

HERON ELAINE J

  • Director
51,968 2020-05-27 2

SPIEGELMAN DANIEL K

  • Director
0 2020-05-27 0

SLAMON DENNIS

  • Director
22,915 2020-05-27 1

GUYER CHARLES GREG EVP, CHIEF TECHNICAL OFFICER

  • Officer
35,040 2020-05-04 2

DAVIS GEORGE ERIC EVP, GENERAL COUNSEL

  • Officer
65,677 2020-04-30 5

MUELLER BRIAN EVP, CHIEF FINANCIAL OFFICER

  • Officer
29,744 2020-04-30 4

AJER JEFFREY ROBERT EVP, CHIEF COMMERCIAL OFFICER

  • Officer
63,402 2020-04-30 7

BAFFI ROBERT PRESIDENT, GLOBAL MFG/TECH OPS

  • Officer
189,020 2020-03-20 3

LAPALME PIERRE

  • Director
19,083 2018-03-05 0

WOOD MARK VP, HUMAN RESOURCES

  • Officer
20,277 2013-05-22 0

SWIEDLER STUART J SVP, CLINICAL AFFAIRS

  • Officer
No longer subject to file 2008-07-07 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-20 M 49,423 d 0 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-20 S 126,389 $130.00 d 102,995 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-20 M 1,250 $67.81 a 104,245 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-20 M 75,716 d 0 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-20 M 49,423 $63.10 a 229,384 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-20 M 1,250 d 0 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-20 M 75,716 $67.81 a 179,961 102,995.00 direct

ACOSTA ANDREA - Officer GVP, CHIEF ACCOUNING OFFICER

2020-07-17 F 285 $128.21 d 14,674 14,674.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-13 M 13,810 d 75,716 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-13 M 8,977 $63.10 a 126,006 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-13 M 224 d 1,250 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-13 M 13,810 $67.81 a 117,029 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-13 M 8,977 d 49,423 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-13 S 23,011 $130.00 d 102,995 102,995.00 direct

FUCHS HENRY J - Officer PRESIDENT, WORLDWIDE R&D

2020-07-13 M 224 $67.81 a 103,219 102,995.00 direct

MUELLER BRIAN - Officer EVP, CHIEF FINANCIAL OFFICER

2020-06-29 A 13,230 a 13,230 29,744.00 direct

MUELLER BRIAN - Officer EVP, CHIEF FINANCIAL OFFICER

2020-06-29 A 4,640 a 29,744 29,744.00 direct

DERE WILLARD H - Director

2020-06-26 S 4,430 $123.61 d 13,290 13,290.00 direct

AJER JEFFREY ROBERT - Officer EVP, CHIEF COMMERCIAL OFFICER

2020-06-19 M 15,000 $63.10 a 78,402 63,402.00 direct

AJER JEFFREY ROBERT - Officer EVP, CHIEF COMMERCIAL OFFICER

2020-06-19 M 15,000 d 15,700 63,402.00 direct

AJER JEFFREY ROBERT - Officer EVP, CHIEF COMMERCIAL OFFICER

2020-06-19 S 15,000 $124.00 d 63,402 63,402.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments